Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Out-licenses China Rights for PD-1 to Pfizer in $480 Million Deal

publication date: Sep 30, 2020

Suzhou CStone Pharma formed a partnership with Pfizer for China commercialization of CStone's PD-1 candidate, sugemalimab. In return for a $200 million investment in CStone, Pfizer will in-license China rights to the candidate. The $200 million will purchase a 10% stake in CStone. Also, CStone will be eligible for up to $280 million in milestones, plus royalties. In addition, the two companies will seek to bring other oncology assets to China. More details....

Stock Symbols: (HK: 2616) (NYSE: PFE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.